Important Clarification First

Additions for Prostate Cancer Prevention

1. PSA-Based Screening (Shared Decision-Making)

• Engage in shared decision-making with your healthcare provider about Prostate-Specific Antigen (PSA) testing, ideally between ages 55 and 69 for average-risk men. The decision should weigh benefits of early detection against risks of overdiagnosis, false positives, and unnecessary biopsies (USPSTF recommendation).
• Men at higher risk - including Black/African-American men, and those with a first-degree relative diagnosed with prostate cancer before age 65 - should consider beginning PSA discussions earlier, at age 40-45.
• For men with low-risk profiles (PSA < 1 ng/mL at age 40, no family history), a screening interval of every 2 to 4 years is reasonable rather than annual testing (AUA guidelines).
• Discuss the significance of your PSA level in context - a single elevated PSA does not confirm cancer, as benign prostatic hyperplasia (BPH) and prostatitis can also raise PSA values.

2. Digital Rectal Examination (DRE)

• In addition to PSA testing, a digital rectal examination (DRE) may be offered as part of prostate cancer screening, particularly when PSA levels are borderline or equivocal. Discuss with your urologist whether DRE is appropriate as part of your individual evaluation.

3. Know Your Family History and Genetic Risk

• Inform your healthcare provider of any family history of prostate cancer, particularly in first-degree relatives (father, brother), or a family history of breast, ovarian, or pancreatic cancer, as these may indicate inherited mutations (e.g., BRCA1/BRCA2, CHEK2, ATM genes) that substantially increase prostate cancer risk (PMID: 36434163; PMID: 39013715).
• Consider genetic counseling and germline testing if you have a strong family history of prostate cancer or multiple cancers across generations. High-risk individuals identified through genetic testing may benefit from earlier and more frequent PSA testing and MRI surveillance.
• Black/African-American men have a significantly higher lifetime risk of prostate cancer and poorer outcomes - tailored screening guidance (such as that from the Prostate Cancer Foundation, 2024) recommends earlier screening initiation for this group (PMID: 38815168).

4. Dietary Modifications

• Adopt a diet rich in fruits, vegetables (especially cruciferous vegetables like broccoli and cabbage), and whole grains, which provide antioxidants and phytonutrients associated with reduced prostate cancer risk.
• Increase intake of lycopene-rich foods (cooked tomatoes, tomato paste), which have shown promising associations with lower prostate cancer risk.
• Limit red and processed meat consumption - high intake has been associated with increased prostate cancer risk in multiple studies.
• Reduce saturated fat and dairy - some studies associate high dairy intake with modestly elevated prostate cancer risk, though evidence remains mixed.
• Limit alcohol consumption, as excessive intake may negatively affect cancer risk broadly.

5. Maintain a Healthy Body Weight

• Obesity (BMI ≥ 30) is associated with a higher risk of aggressive prostate cancer and poorer outcomes. Aim for a healthy body weight through dietary control and regular exercise.
• Weight management strategies should focus on sustainable caloric balance rather than extreme diets.

6. Regular Physical Activity

• Engage in regular aerobic and resistance exercise (most days of the week). Most studies show that physically active men have a lower risk of prostate cancer, particularly aggressive forms, compared with sedentary men (Mayo Clinic, 2025).
• Exercise also provides secondary benefits including weight control, cardiovascular health, and reduced risk of metabolic syndrome - all of which contribute to overall cancer risk reduction.

7. Chemoprevention (Discuss with Your Doctor)

• 5-alpha reductase inhibitors (5-ARIs) such as finasteride and dutasteride have been studied for prostate cancer chemoprevention. The landmark Prostate Cancer Prevention Trial (PCPT) demonstrated a 25% relative reduction in prostate cancer prevalence with finasteride over 7 years, though this was accompanied by a higher prevalence of high-grade (Gleason 8-10) tumors in the treatment group - the clinical significance of this finding remains debated (Campbell-Walsh Wein Urology).
• Chemoprevention with 5-ARIs is not routinely recommended for all men but may be considered for individuals at elevated risk after thorough discussion of benefits and risks with a urologist.
• Vitamin E and selenium supplementation are not recommended - the SELECT trial showed no benefit and potential harm (increased prostate cancer risk with high-dose vitamin E).

8. Avoid Tobacco and Limit Carcinogen Exposure

• Quit smoking - smoking is associated with a higher risk of dying from prostate cancer and may contribute to more aggressive disease.
• Minimize occupational or environmental exposure to cadmium, pesticides, and other recognized carcinogens.

9. Prostate MRI for High-Risk Individuals

• Men with elevated PSA, prior negative biopsy, or known genetic risk factors may benefit from multiparametric MRI (mpMRI) of the prostate to guide decisions about biopsy and ongoing surveillance, rather than proceeding directly to systematic biopsy.

10. Ongoing Risk Reassessment

• Reassess your prostate cancer risk periodically, particularly if your family history changes, new genetic information becomes available, new symptoms develop (urinary hesitancy, weak stream, nocturia, hematospermia, bone pain), or additional risk factors are identified.
• Men who have had a prior negative prostate biopsy but continue to have rising or persistently elevated PSA should remain under active urological surveillance.

Summary of What's Missing vs. What You Have

Additions for Urinary Bladder Cancer Prevention

1. Tobacco Cessation - The Single Most Important Preventable Risk Factor

• Stop smoking in all forms - cigarettes, e-cigarettes, cigars, and pipes. Smoking is the single most important modifiable risk factor, contributing to approximately 50% of all bladder cancers. Current smokers have a 4.1-fold higher risk and former smokers a 2.2-fold higher risk compared to never-smokers (AUA/ASCO/ASTRO/SUO Guideline, 2024).
• Smoking cessation does reduce risk over time, but risk remains elevated for at least 10 years after quitting - this underscores how critical it is to never start, and to quit as early as possible.
• Avoid secondhand smoke exposure, which also independently increases bladder cancer risk.
• The primary carcinogen in tobacco linked to bladder cancer is aminobiphenyl (4-ABP), an aromatic amine that is concentrated and excreted through the urinary tract, exposing the bladder epithelium to prolonged carcinogen contact (Textbook of Family Medicine, 9e).

2. Minimize Occupational Carcinogen Exposure

• Know your occupational risks. Exposure to aromatic amines and other industrial chemicals accounts for approximately 20-25% of bladder cancers in men and 11% in women (AUA Guideline, 2024).
• High-risk occupations include: rubber and tire manufacturing, leather tanning, textile and dye production, painting, metal working, petroleum refining, hairdressing, and truck driving (due to diesel exhaust).
• The primary culprit chemicals are benzidine, 4-aminobiphenyl, 2-naphthylamine, 4-chloro-o-toluidine, polycyclic aromatic hydrocarbons (PAHs), and chlorinated hydrocarbons.
• If you work in any of these industries, follow all occupational health and safety protocols, use appropriate personal protective equipment (PPE), and undergo regular health surveillance.
• Report any new urinary symptoms promptly to your occupational health provider.

3. Adequate Daily Fluid Intake

• Drink adequate amounts of fluids daily, particularly water. Higher fluid intake dilutes potential urinary carcinogens and reduces the contact time between carcinogens and bladder mucosa by increasing voiding frequency.
• General guidance aligns with drinking at least 1.5-2 liters (6-8 glasses) of water per day, adjusted for body size, activity level, and climate.

4. Healthy Diet and Avoidance of Dietary Carcinogens

• Eat a diet rich in fruits and vegetables, which contain antioxidants and phytochemicals that may reduce bladder cancer risk (Emory Winship Cancer Institute guidelines).
• Limit consumption of processed and red meats, particularly charred or grilled meats, which contain PAHs and heterocyclic amines.
• Avoid aristolochic acid - found in certain traditional herbal weight-loss supplements (particularly those containing Aristolochia fangchi). This compound is a potent urothelial carcinogen and is banned in many countries but may still be available in some products (Campbell-Walsh Wein Urology; Textbook of Family Medicine).
• Be cautious with long-term use of cyclophosphamide (a chemotherapy drug) - if prescribed, ask your oncologist about bladder protection strategies (e.g., mesna), as it is a recognized bladder carcinogen.

5. Maintain a Healthy Body Weight and Exercise Regularly

• Obesity and physical inactivity are associated with increased overall cancer risk, including bladder cancer. Maintain a healthy BMI through balanced diet and regular aerobic exercise.

6. Vitamin D Status

• Emerging evidence from a 2026 umbrella review and second-order meta-analysis (PMID: 41814462) found that low serum vitamin D (< 30 nmol/L) is significantly associated with increased bladder cancer risk (RR = 1.32; 95% CI: 1.27-1.38). While evidence on supplementation remains inconclusive, maintaining adequate vitamin D levels through sunlight exposure and dietary sources is a reasonable preventive measure.
• Discuss vitamin D status with your healthcare provider, particularly if you have risk factors for deficiency (limited sun exposure, darker skin, older age).

7. Schistosomiasis Prevention (Squamous Cell Carcinoma of the Bladder)

• In endemic regions (sub-Saharan Africa, Middle East, parts of Asia), infection with Schistosoma haematobium is a major cause of squamous cell carcinoma of the bladder.
• Avoid contact with freshwater sources known to harbor schistosomal cercariae, use clean water for bathing, and seek prompt treatment with praziquantel if exposure occurs.

8. Limit Radiation Exposure to the Pelvis

• Prior pelvic radiation therapy (e.g., for cervical, rectal, or prostate cancer) significantly increases long-term bladder cancer risk. If you have a history of pelvic radiation, inform your healthcare provider so that appropriate bladder surveillance can be arranged.

9. Avoid Prolonged Bladder Foreign Body Exposure

• Prolonged indwelling urinary catheters (e.g., long-term Foley catheters in patients with spinal cord injury or chronic retention) are associated with increased risk of bladder cancer, particularly squamous cell carcinoma. Minimize catheter use when possible; where unavoidable, ensure regular urological follow-up (Campbell-Walsh Wein Urology).

10. Know Your Personal and Family History

• Although bladder cancer is not considered a classical hereditary cancer, first-degree relatives of bladder cancer patients have an elevated risk. Several low-penetrance susceptibility genes have been identified through genome-wide association studies (GWAS), including loci near MYC, TP63, FGFR3, TERT, NAT2, and others (Campbell-Walsh Wein Urology).
• Inform your healthcare provider of any family history of bladder cancer so that an individualized surveillance plan can be developed.
• NAT2 slow acetylator genotype impairs the detoxification of aromatic amines - individuals with this phenotype who have occupational exposure are at particularly elevated risk.

11. Medication Awareness

• Phenacetin-containing analgesics (now largely withdrawn) and long-term use of pioglitazone (a diabetes medication) have been associated with increased bladder cancer risk. If you are taking pioglitazone, discuss the risk-benefit profile with your prescribing doctor.
• Patients who have received cyclophosphamide chemotherapy should be monitored for hematuria and undergo periodic urological evaluation.

Summary: What to Add to Your Existing Content

Additions to Brain Cancer Prevention Clinical Recommendations

1. Ionizing Radiation - The Only Confirmed Modifiable Risk Factor

• Minimize medically unnecessary radiation to the head. Therapeutic ionizing radiation to the cranium is the only well-established modifiable risk factor for primary brain tumors, including gliomas and meningiomas. Brain exposure to ionizing radiation increases tumor risk even years or decades after exposure, including at relatively low doses (Bradley and Daroff's Neurology in Clinical Practice; MDPI Environmental Hazards review, 2024).
• When imaging is clinically necessary, prefer MRI over CT scanning for the brain wherever possible, as MRI involves no ionizing radiation. Discuss the risk-benefit of repeated CT scans with your physician, particularly in children and adolescents, in whom cumulative exposure carries greater long-term risk.
• Avoid unnecessary dental X-rays - multiple lifetime dental X-rays, particularly bitewing X-rays taken annually, have been associated with increased risk of meningioma in some studies.
• If you work in or around radiation-emitting environments (nuclear facilities, radiology, radiotherapy, industrial radiography), ensure strict adherence to personal radiation monitoring protocols, dose limits, and protective shielding guidelines.
• Patients who have previously received cranial radiation therapy (e.g., for childhood leukemia, medulloblastoma, nasopharyngeal carcinoma, tinea capitis) carry a substantially elevated lifetime risk of secondary brain tumors and should undergo long-term neurological surveillance.

2. Identify and Disclose Hereditary Cancer Syndromes

• Inform your healthcare provider if you have a personal or family history of any of the following hereditary syndromes, all of which markedly increase brain tumor risk (Bradley and Daroff's Neurology):
  • Neurofibromatosis type 1 (NF1) - associated with optic gliomas, astrocytomas, and other CNS tumors
  • Neurofibromatosis type 2 (NF2) - associated with bilateral vestibular schwannomas, meningiomas, and ependymomas
  • Li-Fraumeni syndrome (TP53 mutation) - associated with astrocytomas and multiple other cancers
  • Turcot syndrome - associated with glioblastoma and medulloblastoma alongside colorectal polyposis
  • Lynch syndrome (HNPCC) - associated with glioblastoma
  • Cowden syndrome (PTEN mutation) - associated with dysplastic gangliocytoma of the cerebellum
  • Von Hippel-Lindau (VHL) disease - associated with cerebellar and spinal hemangioblastomas
  • Gorlin syndrome (nevoid basal cell carcinoma) - associated with medulloblastoma
• Consider genetic counseling and germline testing if you carry a suspected hereditary syndrome. Individuals with confirmed high-risk mutations should undergo tailored, earlier neurological surveillance.
• Brain tumors in first-degree relatives, even without a named syndrome, confer modestly elevated individual risk due to identified polygenic susceptibility loci (MYC, TP63, TERT, FGFR3, NAT2 and others identified by genome-wide association studies).

3. Occupational Chemical Exposures

• Certain occupational chemical exposures have been associated with elevated brain tumor risk. High-risk industries include:
  • Rubber and synthetic rubber manufacturing
  • Petroleum refining and petrochemical production
  • Pesticide and herbicide manufacturing and use
  • Vinyl chloride production (associated with glioblastoma)
  • Formaldehyde exposure (some evidence for glioma and meningioma)
  • Military and agricultural use of Agent Orange (contains dioxins)
• If employed in these sectors, follow all occupational health and safety protocols, use appropriate personal protective equipment (PPE), and report persistent neurological symptoms to your occupational health provider.
• Minimize home exposure to pesticides and herbicides - use protective gloves and masks when applying these agents and avoid prolonged or repeated skin contact.

4. Mobile Phone and Radiofrequency Electromagnetic Field Use

• The relationship between mobile phone use and brain tumor risk remains one of the most studied and debated questions in neuro-oncology. Current consensus from the WHO and most regulatory agencies is that evidence does not conclusively establish a causal link between mobile phone radiofrequency electromagnetic fields (RF-EMF) and brain tumors at typical exposure levels.
• However, as a prudent precautionary measure, particularly for children and heavy long-term users, consider:
  • Using hands-free devices or speakerphone to reduce direct head contact
  • Limiting call duration when possible
  • Preferring text messaging over voice calls
• Avoid alarmist claims but remain informed as long-term data from large cohort studies continue to emerge.

5. Head Injury Prevention

• Significant traumatic head injury has been suggested as a possible risk factor for some brain tumor types, particularly meningioma, in several case-control studies, though causality is not firmly established.
• Use appropriate head protection (helmets for cycling, motorcycling, contact sports, construction work) to prevent traumatic brain injury - this carries benefits well beyond cancer risk reduction.

6. Maintain a Healthy Lifestyle and Immune Function

• Maintain a healthy body weight. While a direct causal relationship between obesity and primary brain tumors is not firmly proven, general metabolic health supports overall cancer risk reduction.
• Follow an anti-inflammatory dietary pattern. A Mediterranean-style diet rich in antioxidants, healthy fats (omega-3 fatty acids from fish), colorful fruits and vegetables, whole grains, and cruciferous vegetables (broccoli, cabbage, cauliflower - which contain isothiocyanates that have shown anti-glioma activity in preclinical studies) may support brain health and reduce general cancer risk (Loma Linda University Neuro-Oncology; PMC glioma diet review).
• Limit processed meats and N-nitroso compounds (NOC). Cured and processed meats (bacon, hot dogs, salted fish) contain nitrosamines and NOC, which were historically hypothesized to be brain tumor carcinogens. While large prospective cohort data have not confirmed a strong causal role, limiting processed meat intake remains prudent (Bradley and Daroff's Neurology).
• Vitamin D adequacy. Vitamin D receptor is expressed in glioma tissue, and emerging preclinical and observational evidence suggests vitamin D metabolites may have anti-proliferative effects on brain tumor cells. Maintain adequate vitamin D levels through safe sun exposure and dietary sources.
• Engage in regular physical activity. Regular aerobic exercise supports systemic immune function, reduces inflammatory markers, and is associated with reduced risk of multiple cancers.
• Avoid tobacco. Although current evidence does not establish smoking as a direct causal risk factor for adult gliomas, tobacco's broad carcinogenic and pro-inflammatory effects make avoidance a reasonable general cancer prevention measure.

7. Protect Children from Cranial Radiation

• Children are substantially more radiosensitive than adults. Minimize unnecessary cranial CT scanning in the pediatric population. Where possible, request that imaging centers use pediatric-adjusted low-dose protocols.
• Childhood cancer survivors who received cranial radiation should be enrolled in long-term follow-up surveillance programs covering late neurological effects including secondary brain tumors, which may emerge 10-30 years after treatment.

8. Awareness of Viral and Immune Factors (Emerging Evidence)

• Certain viral infections have been investigated as potential contributors to brain tumor risk. Cytomegalovirus (CMV) antigens have been detected in a high proportion of glioblastoma specimens, though whether CMV plays a causal role or is an opportunistic infection remains under active investigation.
• Interestingly, a robust finding across multiple epidemiological studies is that individuals with a history of allergies or atopic conditions (asthma, eczema, hay fever) have a 39% lower risk of glioma (summary RR 0.61; 95% CI 0.55-0.67), suggesting that heightened immune surveillance may confer protection (Bradley and Daroff's Neurology, multiple meta-analyses). This is a descriptive observation - it does not imply any actionable preventive intervention.
• Maintain up-to-date vaccination status against known oncogenic viruses (e.g., HPV) as part of a broad cancer prevention strategy.

9. Mental Health and Psychosocial Support Awareness

• A brain tumor diagnosis carries one of the highest rates of psychological distress and suicidal ideation among all cancer types (Kaplan & Sadock's Comprehensive Textbook of Psychiatry). Patients with neurological symptoms under investigation should be screened for anxiety and depression.
• Ensure access to psychological and social support services throughout the evaluation process, not only after a confirmed diagnosis.

10. Clarification on Screening

• No validated population-level screening test exists for primary brain tumors in asymptomatic individuals. Routine brain MRI for asymptomatic low-risk individuals is not recommended by any major guideline body and may lead to detection of incidental findings, over-investigation, and patient anxiety.
• Screening neuroimaging should be reserved for individuals with confirmed high-risk hereditary syndromes (e.g., NF1, NF2, Li-Fraumeni) or prior cranial radiation exposure, in consultation with a specialist.

Summary: Gaps in Your Existing Content

Additions to Clinical Recommendations: Hereditary Paraganglioma - Genetic High Risk

1. Surveillance Age Commencement - Gene-Specific Guidance

• Begin formal surveillance at age-appropriate, gene-specific intervals rather than waiting for adulthood. Current consensus guidance (UK Cancer Genetics Group, 2025; Wong et al. Clinical Practice Guidance) recommends:
  • SDHB carriers: Annual clinical examination with blood pressure and biochemical screening (plasma metanephrines) from age 5 years; abdominal MRI from age 10 years; MRI of neck and thorax from age 14-16 years
  • SDHA, SDHC, SDHD carriers: Biochemical screening from age 10 years (annual from age 18); MRI surveillance from age 15 years
  • SDHD and SDHAF2: Due to maternal imprinting, maternally inherited variants rarely cause disease, but all carriers should be counseled about a 50% risk of passing the variant to offspring
• If you are an asymptomatic SDHB carrier with no tumor detected by age 70, surveillance continues at ages 75 and 80, after which further surveillance may be discontinued - this decision must be made with your specialist team.

2. Gene-Specific Associated Tumors Beyond Paraganglioma

• SDHB, SDHC, SDHD, SDHA: Associated not only with paraganglioma and pheochromocytoma but also with gastrointestinal stromal tumors (GIST), renal cell carcinoma (particularly clear cell or papillary subtypes), and pituitary adenoma. Symptoms suggestive of these tumors (abdominal pain, blood in urine, hormonal changes, visual field defects) should prompt prompt reporting to your specialist (Braunwald's Heart Disease; UKCGG Guidelines 2025).
  • Note: Routine imaging surveillance specifically for GIST, renal cell carcinoma, or pituitary adenoma is not recommended in the absence of suggestive symptoms - discuss the threshold for investigation with your specialist.
• MAX mutation carriers: Bilateral adrenal pheochromocytomas occur in approximately 67% and malignant behavior in approximately 25% - awareness of bilateral disease risk should be specifically discussed.
• TMEM127 mutation carriers: Predominantly adrenal catecholamine-secreting pheochromocytoma; bilateral tumors develop in up to one-third of patients; associated malignancy rate is low (<5%) (Braunwald's Heart Disease).
• MEN2A (RET): Associated with medullary thyroid carcinoma and primary hyperparathyroidism in addition to pheochromocytoma - a calcium level check and thyroid evaluation should be part of regular review.
• MEN2B (RET): Associated with medullary thyroid carcinoma, mucosal neuromas (visible on lips and tongue), and marfanoid habitus - if you notice bumpy lesions on the lips or tongue, report these to your endocrinologist.
• VHL: Associated with cerebellar/spinal hemangioblastomas, retinal angiomas, clear cell renal cell carcinoma, pancreatic cysts and tumors, and endolymphatic sac tumors - all of which require separate, dedicated surveillance protocols.
• NF1: Associated with neurofibromas, café-au-lait spots, optic glioma, and learning difficulties - multi-disciplinary surveillance including ophthalmology and neurology is appropriate.

3. Pre-Pregnancy and Reproductive Planning

• If you are of reproductive age and carry a hereditary paraganglioma gene variant, it is strongly recommended that biochemical screening (plasma metanephrines) is performed and confirmed normal before attempting pregnancy (eviQ Cancer Genetics, 2024 version).
• Undiagnosed or untreated secretory paraganglioma during pregnancy carries a high risk of life-threatening hypertensive crises for both mother and baby, with significant maternal and fetal mortality if unrecognized (Creasy & Resnik's Maternal-Fetal Medicine; Frontiers in Oncology, 2025).
• In the event of pregnancy, inform your obstetric team and endocrinologist at the earliest opportunity. Management of paraganglioma during pregnancy requires a multidisciplinary team including endocrinology, obstetrics, and surgery.
• MRI is the preferred imaging modality during pregnancy due to the absence of ionizing radiation. CT scanning should be avoided in pregnancy unless no alternative exists.
• Alpha-adrenergic blockade is the cornerstone of pharmacological management in pregnancy if a secretory tumor is identified; beta-blockers must only be added after adequate alpha-blockade is established to prevent paradoxical hypertensive crisis.
• Discuss the 50% risk of passing the genetic variant to offspring with your genetics team. Prenatal genetic testing and pre-implantation genetic diagnosis (PGD/IVF) options are available and can be explored with a clinical genetics service.

4. Pre-Surgical and Perioperative Safety Planning

• Before any surgical or invasive procedure, your surgical and anaesthetic team must be informed of your genetic predisposition and any known or suspected paraganglioma. This point is already included in your content but should be expanded:
• Biochemical testing with plasma metanephrines should be performed before planned surgery of any kind, even if no paraganglioma has been previously identified, to exclude occult hormone-secreting tumors (eviQ, 2024).
• Surgical resection of paraganglioma requires pre-operative pharmacological preparation with alpha-adrenergic blockade (typically phenoxybenzamine or doxazosin) for a minimum of 7-14 days, followed by beta-blockade if needed and adequate fluid and salt loading, to prevent intraoperative hypertensive crisis (Braunwald's Heart Disease; Mulholland and Greenfield's Surgery).
• Where surgically and anatomically feasible, cortical-sparing (partial) adrenalectomy should be discussed with your surgeon, particularly for MEN2 and VHL patients, to preserve residual adrenocortical function and avoid lifelong steroid replacement.
• Following successful surgical removal of a paraganglioma, post-operative biochemical re-evaluation (plasma metanephrines, 3-methoxytyramine) should be performed at 6 weeks post-surgery, and subsequent tailored surveillance discussed at a specialist multidisciplinary team (MDT) meeting (UKCGG 2025).

5. Functional Imaging - 68Ga-DOTATATE PET/CT

• In addition to anatomical MRI, your specialist may recommend 68Gallium-DOTATATE PET-CT or PET-MRI (a functional imaging scan that uses a radioactive tracer targeting somatostatin receptors on paraganglioma cells). This scan has superior sensitivity for detecting small, multifocal, or metastatic paragangliomas compared to conventional CT or MRI alone.
• This scan is typically recommended at initial assessment (particularly for adults commencing surveillance at age 18 or older) and in specific clinical scenarios such as abnormal biochemistry with negative anatomical imaging, or when metastatic disease is suspected (eviQ Guideline Version 4, 2024).
• MIBG (metaiodobenzylguanidine) scintigraphy is an alternative functional imaging modality, particularly useful for catecholamine-secreting tumors. Discuss with your specialist which functional imaging is most appropriate for your gene variant and clinical situation.

6. Lifestyle Modifications for Carriers

• While no specific lifestyle intervention has been proven to prevent paraganglioma tumor development in gene carriers, general cancer-risk-reduction principles apply (eviQ Guideline):
  • Exercise for at least 30 minutes at moderate to vigorous intensity on most days of the week
  • Maintain a healthy body weight
  • Follow a balanced diet rich in fruits, vegetables, whole grains, and lean proteins, which may support mitochondrial health and cellular resilience - relevant given that SDH gene mutations impair mitochondrial complex II function and increase oxidative stress
  • Limit alcohol intake
  • Do not smoke and avoid passive smoking - smoking may exacerbate oxidative stress and interfere with oxygen-sensing pathways already perturbed in SDH-deficient cells
  • Avoid excessive sun exposure and follow general cancer prevention guidelines
• Avoid stimulant drugs and recreational substances (cocaine, amphetamines, MDMA) which can provoke hypertensive crisis in the context of a catecholamine-secreting tumor.
• Limit dietary caffeine in high doses if you have a known secretory tumor - large caffeine doses can transiently raise blood pressure.

7. Psychological Support and Quality of Life

• Living with a hereditary cancer predisposition syndrome such as hereditary paraganglioma carries significant psychological burden, including health anxiety, fear of cancer development, concerns about family members, and the impact of repeated surveillance procedures.
• Seek access to psychological support services, including cancer genetic counselors, clinical psychologists, or peer support groups specializing in hereditary cancer syndromes, particularly after receiving genetic test results or following a new tumor diagnosis.
• Patient support organizations such as the Pheo Para Alliance and VHL Alliance provide condition-specific peer support, educational resources, and specialist referral networks.
• Discuss the emotional and practical impact of cascade family testing with your genetics team before informing relatives, as genetic test results can affect family relationships, insurance, and employment in some jurisdictions.

8. Long-Term Post-Treatment Surveillance After Tumor Resection

• Even after successful complete surgical resection of a paraganglioma, lifelong surveillance is required because of the risk of tumor recurrence, development of new tumors at different sites (particularly in multifocal syndromes such as SDHD), and late metastatic presentation - especially in SDHB carriers where metastatic disease may appear years after initial surgery.
• SDHB carriers with previously resected paraganglioma face the highest risk of late metastasis and should adhere strictly to post-operative surveillance schedules, which typically involve annual biochemical testing and periodic whole-body MRI (UKCGG 2025; Nature Reviews Endocrinology 2024 Consensus).
• After resection of a bilateral adrenal pheochromocytoma, monitor for signs of adrenal insufficiency (fatigue, postural dizziness, weight loss, salt craving, low blood pressure). You may require hydrocortisone replacement - carry an emergency steroid card and know how to take sick-day dosing.

9. Blood Pressure Monitoring - Practical Guidance

• Use a validated upper-arm automated blood pressure monitor rather than wrist devices for reliable readings.
• Record and keep a blood pressure diary including date, time, both readings per session, and any associated symptoms (headache, palpitation, sweating), and bring this log to every clinic appointment.
• A blood pressure reading of ≥ 150/100 mmHg or any reading accompanied by symptoms such as severe headache, palpitations, or diaphoresis should prompt same-day medical contact, not merely a note for the next scheduled appointment.
• Be aware that paradoxical orthostatic hypotension (dizziness on standing) can occur alongside hypertension in pheochromocytoma/paraganglioma due to volume depletion and baroreceptor dysfunction - report this symptom to your doctor.

Summary: What Was Added vs. What Was Already Present